Nov 13, 2026 6:19 am EST Rezolute Announces Pricing of Approximately $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Nov 13, 2026 6:18 am EST Rezolute Announces Positive Results from the Phase 3 upLIFT Study in Tumor Hyperinsulinism
Nov 5, 2026 4:05 pm EST Rezolute Reports First Quarter Fiscal 2027 Financial Results and Provides Business Update
Oct 14, 2026 4:05 pm EDT Rezolute Announces Completion of Enrollment in Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism
Oct 5, 2026 7:00 am EDT Rezolute Announces FDA Recommendation to Hold a Pre-BLA Meeting as a Precursor to Submitting a Biologics License Application (BLA) for Congenital Hyperinsulinism
Sep 24, 2026 4:05 pm EDT Rezolute Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Business Update
Sep 9, 2026 7:00 am EDT Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism
